将脐带血组织来源的间充质基质细胞加入 Ruxolitinib 治疗类固醇难治性急性移植物抗宿主病
两种剂量的脐带血组织来源的间充质基质细胞联合 Ruxolitinib 与 Ruxolitinib 单独治疗类固醇难治性急性移植物抗宿主病的随机对照试验研究
This early phase I trial is to find out the effect of adding cord blood tissue-derived mesenchymal stromal cells (cb-MSCs) to ruxolitinib in treating patients with acute graft versus host disease that does not respond to steroid therapy (steroid-refractory). Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. cb-MSCs are a type of tissue helper cell that can be removed from donated umbilical cord blood tissue and grown into many different cell types that can be used to treat cancer and other disease, such as graft versus host disease. This trial aims to learn if adding cb-MSCs to ruxolitinib may help control steroid-refractory acute graft versus host disease.
研究概览
详细说明
PRIMARY OBJECTIVE:
I. To estimate between-arm differences (Arm 3 versus [vs] Arm 1, and Arm 2 vs Arm 1) for each of the 28-day co-primary outcome probabilities.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM 1: Patients receive ruxolitinib orally (PO) twice daily (BID) for at least 3 days and may consider tapering after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued.
ARM 2: Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive lower dose of cb-MSCs intravenously (IV) for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
ARM 3: Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive higher dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
After completion of study treatment, patients are followed up on day 28 and then for up to 6 months.
研究类型
注册 (估计的)
阶段
- 第一阶段早期
联系人和位置
学习联系方式
- 姓名:Partow Kebriaei, MD
- 电话号码:713-745-0663
- 邮箱:pkebriae@mdanderson.org
学习地点
-
-
Texas
-
Houston、Texas、美国、77030
- 招聘中
- M D Anderson Cancer Center
-
接触:
- Partow Kebriaei, MD
- 电话号码:713-745-0663
- 邮箱:pkebriae@mdanderson.org
-
首席研究员:
- Partow Kebriaei, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Participants between the ages of 12 years and 80 years (inclusive).
- Steroid refractory grades II-IV acute GVHD of the Lower GI tract or Liver (including those developing these manifestations after previous acute GVHD of skin) secondary to allogeneic HCT or donor lymphocyte infusion. (Grading, see Appendix I) GVHD with: No improvement after treatment with methylprednisolone at ≥ 2.0 mg/kg/day or equivalent for minimum 7 days, or progressive symptoms after minimum 3 days, or a flare in acute GVHD while on systemic steroids. Participants must have had a biopsy that suggests GVHD; a repeat biopsy to enroll on the study is not necessary.
- Karnofsky/Lansky Performance score of at least 30 at the time of study entry.
- Participants who are women of childbearing potential, must be non-pregnant, not breast-feeding, and use adequate contraception. Male patients must use adequate contraception
- Participants (or legal representative where appropriate) must be capable of providing written informed consent, and assent if indicated.
Exclusion Criteria:
- De novo chronic GVHD
- Isolated acute GVHD of skin
- Secondary systemic therapy for acute GVHD ruxolitinib greater than 96 hours before initiation of therapy.
- Primary treatment with agents other than alpha-1 antitrypsin (AAT) glucocorticoids and ruxolitinib.
- Participants with uncontrolled infections will be excluded. Infections are considered controlled if appropriate therapy has been instituted and, at the time of enrollment, no signs of progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
- Adult and pediatric patients with cognitive impairments and/or any serious unstable pre-existing medical condition or psychiatric disorder that can interfere with safety or with obtaining informed consent or compliance with study procedures.
- Participants with significant supplemental oxygen requirement defined as >6 L oxygen by nasal cannula.
- Participants with known allergy to bovine or porcine products.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Arm 1 (ruxolitinib)
Patients receive ruxolitinib PO BID for at least 3 days and may consider tapering after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued. |
Given PO
其他名称:
|
|
实验性的:Arm 2 (ruxolitinib, lower dose ds-MSCs)
Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive lower dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses. |
Given PO
其他名称:
Given ds-MSCs IV
其他名称:
|
|
实验性的:Arm 3 (ruxolitinib, higher dose ds-MSCs)
Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive higher dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses. |
Given PO
其他名称:
Given ds-MSCs IV
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
因任何原因死亡
大体时间:积极研究治疗开始后 28 天内
|
积极研究治疗开始后 28 天内
|
|
|
不良事件发生率
大体时间:积极研究治疗开始后 28 天内
|
积极研究治疗开始后 28 天内
|
|
|
Response
大体时间:At day 28 from start of therapy on study
|
Will compare the patient's 28-day graft versus host disease (GVHD) status to the patient's baseline GVHD status when steroid refractory acute GVHD was diagnosed. |
At day 28 from start of therapy on study
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
每个器官的完全反应发生率
大体时间:长达 6 个月
|
长达 6 个月
|
|
|
每个器官非常好的部分反应的发生率
大体时间:长达 6 个月
|
长达 6 个月
|
|
|
每个器官的部分反应发生率
大体时间:长达 6 个月
|
长达 6 个月
|
|
|
器官反应的持久性
大体时间:长达 6 个月
|
长达 6 个月
|
|
|
非复发死亡率 (NRM) 的累积发生率
大体时间:治疗后 6 个月
|
治疗后 6 个月
|
|
|
原发疾病复发/进展的累积发生率
大体时间:6个月时
|
6个月时
|
|
|
总生存期
大体时间:从入组到因任何原因死亡,在 6 个月时评估
|
从入组到因任何原因死亡,在 6 个月时评估
|
|
|
无病生存
大体时间:从入组到任何原因导致的死亡或原发疾病的复发/进展,在 6 个月时进行评估
|
从入组到任何原因导致的死亡或原发疾病的复发/进展,在 6 个月时进行评估
|
|
|
任何级别细胞因子释放的发生率
大体时间:完成最后一次 MSC 输注研究药物后最多 28 天
|
完成最后一次 MSC 输注研究药物后最多 28 天
|
|
|
任何输注毒性的发生率
大体时间:每次脐带血-MSC输注后24小时内
|
每次脐带血-MSC输注后24小时内
|
|
|
Graft versus host disease status
大体时间:At days 7, 14, 21 and 28 post treatment
|
Will assess complete response (CR), very good partial response (VGPR), partial response (PR), stable disease (SD), and progressive disease (PD). |
At days 7, 14, 21 and 28 post treatment
|
|
Proportion of response
大体时间:At days 7, 14, 21 and 28 post treatment
|
Will assess proportion of patients with CR, PR, VGPR, and no-response (NR). The event NR is defined as stable disease, mixed response, disease progression, OR initiation of additional systemic (second-line) GVHD therapies. |
At days 7, 14, 21 and 28 post treatment
|
|
Time to complete response
大体时间:Up to 6 months
|
Will be estimated by the method of Kaplan and Meier. |
Up to 6 months
|
|
Time to very good partial response
大体时间:Up to 6 months
|
Will be estimated by the method of Kaplan and Meier. |
Up to 6 months
|
|
Time to partial response
大体时间:Up to 6 months
|
Will be estimated by the method of Kaplan and Meier. |
Up to 6 months
|
|
Graft versus host disease-free survival
大体时间:At 6 months
|
Patients alive, free of active acute or chronic GVHD, and without other systemic agents (or escalation of steroids to >= 2.5 mg/kg/day of prednisone [or methylprednisolone equivalent of 2 mg/kg/day]) added for treatment of GVHD will be considered successes for this endpoint |
At 6 months
|
|
Incidence of chronic graft versus host disease
大体时间:At 6 months after first mesenchymal stromal cells (MSC) infusion
|
Chronic GVHD is defined per National Institutes of Health Consensus Criteria. Diagnosis of chronic GVHD of any severity (mild, moderate, or severe) is considered an event for this endpoint. Organ involvement and maximum severity will also be described at six months. |
At 6 months after first mesenchymal stromal cells (MSC) infusion
|
|
Incidence of systemic infections
大体时间:28 days after last study drug
|
The incidence of grade 2 to 3 systemic infections occurring from study treatment until 28 days after last study drug will be described using standard Common Terminology Criteria for Adverse Events (CTCAE) criteria. Infections will be recorded by site of disease, date of onset, and severity. |
28 days after last study drug
|
|
Incidence of toxicities
大体时间:Up to 28 days after completing last MSC infusion study drug
|
The incidence of grade 3-5 treatment-emergent adverse events (per CTCAE version 5.0) that occur through 28 days after completing last MSC infusion study drug will be described. |
Up to 28 days after completing last MSC infusion study drug
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Cytokine biomarker analysis (optional)
大体时间:Up to 6 months
|
Will use cytokine biomarker assays to predict response to therapy. |
Up to 6 months
|
|
Fecal samples analysis (optional)
大体时间:Up to 6 months
|
Will use fecal samples to assess microbiome and potential predictor for response to therapy. |
Up to 6 months
|
合作者和调查者
调查人员
- 首席研究员:Partow Kebriaei, MD、M.D. Anderson Cancer Center
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.